These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27776351)

  • 1. Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis.
    Park JO; Ryoo BY; Yen CJ; Kudo M; Yang L; Abada PB; Cheng R; Orlando M; Zhu AX; Okusaka T
    Oncotarget; 2016 Nov; 7(46):75482-75491. PubMed ID: 27776351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
    Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
    Kudo M; Hatano E; Ohkawa S; Fujii H; Masumoto A; Furuse J; Wada Y; Ishii H; Obi S; Kaneko S; Kawazoe S; Yokosuka O; Ikeda M; Ukai K; Morita S; Tsuji A; Kudo T; Shimada M; Osaki Y; Tateishi R; Sugiyama G; Abada PB; Yang L; Okusaka T; Zhu AX
    J Gastroenterol; 2017 Apr; 52(4):494-503. PubMed ID: 27549242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
    Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
    Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
    Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AX
    J Gastroenterol; 2020 Jun; 55(6):627-639. PubMed ID: 32107609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.
    Zhu AX; Finn RS; Mulcahy M; Gurtler J; Sun W; Schwartz JD; Dalal RP; Joshi A; Hozak RR; Xu Y; Ancukiewicz M; Jain RK; Nugent FW; Duda DG; Stuart K
    Clin Cancer Res; 2013 Dec; 19(23):6614-23. PubMed ID: 24088738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL).
    Park K; Kim JH; Cho EK; Kang JH; Shih JY; Zimmermann AH; Lee P; Alexandris E; Puri T; Orlando M
    Cancer Res Treat; 2016 Oct; 48(4):1177-1186. PubMed ID: 26910471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer.
    Chung HC; Kok VC; Cheng R; Hsu Y; Orlando M; Fuchs C; Cho JY
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):204-209. PubMed ID: 29318751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
    Chau I; Peck-Radosavljevic M; Borg C; Malfertheiner P; Seitz JF; Park JO; Ryoo BY; Yen CJ; Kudo M; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Okusaka T; Bowman L; Cui ZL; Girvan AC; Abada PB; Yang L; Zhu AX
    Eur J Cancer; 2017 Aug; 81():17-25. PubMed ID: 28591675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer.
    Muro K; Oh SC; Shimada Y; Lee KW; Yen CJ; Chao Y; Cho JY; Cheng R; Carlesi R; Chandrawansa K; Orlando M; Ohtsu A
    J Gastroenterol Hepatol; 2016 Mar; 31(3):581-9. PubMed ID: 26317322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ramucirumab and its use in the treatment of hepatocellular carcinoma.
    Turkes F; Chau I
    Future Oncol; 2019 Mar; 15(9):979-988. PubMed ID: 30644314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.
    Chau I; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Kudo M; Pfiffer T; Hatano E; Chung HC; Kopeckova K; Phelip JM; Brandi G; Ohkawa S; Li CP; Okusaka T; Hsu Y; Abada PB; Zhu AX
    Br J Cancer; 2018 Jul; 119(1):19-26. PubMed ID: 29808014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
    Kudo M; Galle PR; Llovet JM; Finn RS; Vogel A; Motomura K; Assenat E; Merle P; Brandi G; Daniele B; Okusaka T; Tomášek J; Borg C; Dadduzio V; Morimoto M; Pracht M; Jen MH; Drove Ubreva N; Widau RC; Shinozaki K; Yoshikawa R; Zhu AX
    Liver Int; 2020 Aug; 40(8):2008-2020. PubMed ID: 32279446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials.
    Llovet JM; Singal AG; Villanueva A; Finn RS; Kudo M; Galle PR; Ikeda M; Callies S; McGrath LM; Wang C; Abada P; Widau RC; Gonzalez-Gugel E; Zhu AX
    Clin Cancer Res; 2022 Jun; 28(11):2297-2305. PubMed ID: 35247922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
    Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
    JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab.
    Reig M; Galle PR; Kudo M; Finn R; Llovet JM; Metti AL; Schelman WR; Liang K; Wang C; Widau RC; Abada P; Zhu AX
    Liver Int; 2021 Mar; 41(3):598-607. PubMed ID: 33188713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
    Kim TY; Yen CJ; Al-Batran SE; Ferry D; Gao L; Hsu Y; Cheng R; Orlando M; Ohtsu A
    Gastric Cancer; 2018 Mar; 21(2):276-284. PubMed ID: 28634748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study.
    Hatanaka T; Naganuma A; Shibasaki M; Kohga T; Arai Y; Nagashima T; Ueno T; Namikawa M; Saito S; Hoshino T; Takizawa D; Arai H; Makita F; Kakizaki S; Harimoto N; Shirabe K; Uraoka T
    Oncology; 2021; 99(4):203-214. PubMed ID: 33279908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
    Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
    Trojan J; Mollon P; Daniele B; Marteau F; Martín L; Li Y; Xu Q; Piscaglia F; Zaucha R; Sarker D; Lim HY; Venerito M
    Adv Ther; 2021 May; 38(5):2472-2490. PubMed ID: 33822328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.